Systemic and local immune response in pigs intradermally and intramuscularly injected with inactivated Mycoplasma hyopneumoniae vaccines

Martelli, Paolo; Saleri, Roberta; Cavalli, Valeria; Angelis, Elena De; Ferrari, Luca; Benetti, Michele; Ferrarini, Giulia; Merialdi, G.; Borghetti, Paolo

doi:10.1016/j.vetmic.2013.11.025

Cited by 43 publications

(40 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…immunized pigs. 71 Mice intradermally immunized with a HPV DNA vaccine together with a CTB plasmid vector generated high antigen-specific IgA and IgG titers in cervical secretions and feces, and showed enhanced CTL activity and Th1 (IL-2 and IFN-g) cytokine expression in spleen. 72 Interestingly, i.d.…”

Section: Intradermal Immunizationmentioning

confidence: 99%

Induction of mucosal immunity through systemic immunization: Phantom or reality?

Patel

et al. 2016

Human Vaccines & Immunotherapeutics

132

View full text Add to dashboard Cite

Section: Intradermal Immunizationmentioning

confidence: 99%

Induction of mucosal immunity through systemic immunization: Phantom or reality?

Patel

et al. 2016

Human Vaccines & Immunotherapeutics

132

View full text Add to dashboard Cite

“…A number of previously reported studies have emphasized the benefits from such routine vaccination programmes either after intramuscular [10, 11] or intradermal administration [3, 11], against the negative impact of EP on health and productive parameters of infected pigs. However, despite the extensive vaccination efforts in the vast majority of swine farms worldwide, M. hyo remains a major problem [12].…”

Section: Introductionmentioning

confidence: 99%

Field efficacy study of a novel ready-to-use vaccine against mycoplasma hyopneumoniae and porcine circovirus type 2 in a Greek farm

Tzika

Tassis

Koulialis³

et al. 2015

Porc Health Manag

View full text Add to dashboard Cite

BackgroundThe primary objective of this study was to assess the efficacy, under field conditions, of a novel ready-to use Mycoplasma hyopneumoniae (M hyo) and Porcine circovirus type 2 (PCV2) combination vaccine given to piglets as one vaccination (1-shot) at 3 weeks of age. The study was carried out according to a controlled, randomised, and blinded design in a Greek pig herd with clinical M. hyo and subclinical PCV2 infection. Moreover, based on serology at the time of vaccination, the average PCV2 titre was 9.15 log2 and represented the level of maternally derived antibodies (MDA). In total 602 healthy suckling piglets, originating from 4 weekly farrowing batches were allocated randomly, within litters, to one of two groups. The pigs in one group were vaccinated with the test product and the other pigs were injected with saline.ResultsVaccination significantly reduced lesions of craneo-ventral pulmonary consolidation in vaccinated group [expressed as lung lesion score (LLS)] (Mixed model ANOVA: p < 0.0001). The mean LLS was 17.1 in the controls and 10.6 in the treatment group, respectively. The average daily weight gain (ADWG) during the finishing (54 g better in the treatment group) and whole study period (34 g better in vaccinated animals) was significantly greater in vaccinated than control pigs. The vaccinated pigs had a significant reduction of PCV2 viraemia when compared with the controls.ConclusionsThe test product was considered effective in the face of average MDA, based on significantly reduced severity of LLS and PCV2 viral load, as well as improved ADWG in vaccinated versus control pigs.

show abstract

“…The IDAL Ò device is developed for use in pigs and has previously only been used in pig studies. [33][34][35][36] The immunization of rabbits with the IDAL Ò device was successful in the current study and the desired deposition of the vaccine into the dermis layers was evaluated immediately after injections with colored liquid in a single rabbit (Fig. 2).…”

Section: Needle-free Delivery Of Dna Vaccine Elicits Antibody Responsmentioning

confidence: 84%

“…Different needle-free injection systems have been tested successfully with influenza DNA plasmids in animals 21,32 and humans. 11 The needle-less IDAL Ò vaccinator (MSD Animal Health, Summit, NJ, US) is already used routinely for vaccination in swine herds for attenuated and inactivated protein vaccines against the Porcine Reproductive and Respiratory Syndrome virus, 33 Aujeszky's disease virus 34 and Mycoplasma hyopneumoniae 35,36 with promising results. Previously, we have demonstrated cross-protective immunity in ferrets and pigs from DNA vaccines with pandemic genes of the 1918 H1N1-, 1968 H3N2-and pdm09 H1N1-influenza virus.…”

Section: Introductionmentioning

confidence: 99%

Vector optimization and needle-free intradermal application of a broadly protective polyvalent influenza A DNA vaccine for pigs and humans

Borggren

Nielsen

Bragstad

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Systemic and local immune response in pigs intradermally and intramuscularly injected with inactivated Mycoplasma hyopneumoniae vaccines

Cited by 43 publications

References 22 publications

Induction of mucosal immunity through systemic immunization: Phantom or reality?

Induction of mucosal immunity through systemic immunization: Phantom or reality?

Field efficacy study of a novel ready-to-use vaccine against mycoplasma hyopneumoniae and porcine circovirus type 2 in a Greek farm

Vector optimization and needle-free intradermal application of a broadly protective polyvalent influenza A DNA vaccine for pigs and humans

Contact Info

Product

Resources

About